The clinical stakes are considerable. Bronchopulmonary dysplasia, defined by the need for supplemental oxygen or respiratory support at a corrected gestational age of thirty-six weeks, affects a substantial proportion of infants born before twenty-eight weeks of gestation and is associated with long-term respiratory morbidity, neurodevelopmental impairment, and rehospitalization throughout childhood. Its pathogenesis is multifactorial, involving inflammation, infection, hyperoxia exposure, impaired alveolar and vascular development, and genetic and environmental interactions. Because no single therapy has proven reliably protective, clinicians scrutinize every drug that reaches the developing lung for possible harm, and the analgesics and anti-inflammatory agents used in the first weeks of life are no exception.

The story of these drugs in the neonatal intensive care unit begins with the ductus arteriosus itself. Increased blood flow across a patent ductus arteriosus can be associated with increased pulmonary blood circulation and morbidity, a hemodynamic burden that physicians have tried to relieve since the latter part of the twentieth century by closing a hemodynamically significant ductus in the hope of improving outcomes. The pharmacological workhorses of that effort have been cyclooxygenase inhibitors, chiefly indomethacin and ibuprofen, which reduce prostaglandin signaling and allow the vessel to constrict and close. Both drugs have been used extensively for ductal closure, but both carry side effects and safety concerns in preterm infants, including effects on renal perfusion, gastrointestinal integrity, and platelet function, concerns that have driven a decades-long search for alternatives.

That search produced one of the more memorable accidental discoveries in modern neonatology. As recounted by Sharma and Bhandari, Hammerman and colleagues observed that the use of acetaminophen in preterm infants led to closure of the patent ductus arteriosus, a finding reported in case series that surprised many observers. The mechanism is plausible: acetaminophen acts on prostaglandin synthesis through pathways distinct from classical cyclooxygenase inhibition, and the ductus in the preterm infant remains sensitive to even modest reductions in prostaglandin activity. Following those initial case reports, multiple trials demonstrated that acetaminophen was as effective in closing the ductus as the two established non-steroidal anti-inflammatory drugs, ibuprofen and indomethacin. Crucially, those studies did not look only at closure rates; they also examined associated morbidities, and bronchopulmonary dysplasia emerged as the outcome of greatest interest.

The evidence on that outcome, however, has been reassuringly consistent so far. A large multicenter trial conducted by Gupta and colleagues, published in the New England Journal of Medicine, showed no significant difference in the incidence of bronchopulmonary dysplasia between groups of infants treated with ibuprofen and those given placebo. A retrospective study by Jensen and colleagues compared one group of infants receiving acetaminophen with another receiving ibuprofen or indomethacin and found that the incidence of death or grade 2 to 3 bronchopulmonary dysplasia was similar in both groups. These findings suggested that neither class of drug, when used for ductal closure, clearly worsens the risk of chronic lung disease, at least within the populations and dosing regimens studied.

The BeNeDuctus trial added an important dimension to this debate. This large multicenter randomized non-inferiority trial compared expectant management of a significant patent ductus arteriosus, meaning careful observation without immediate drug treatment, against early treatment with ibuprofen. The trial showed no difference in the incidence of bronchopulmonary dysplasia, necrotizing enterocolitis, or death between the two management strategies. That result was consequential in its own right, because it suggested that routine early pharmacological closure of the ductus may not be necessary for all affected infants. But it also created an unexpected opportunity: some patients in both subgroups received acetaminophen, not for ductal closure but for analgesia, meaning the trial inadvertently enrolled a cohort of extremely preterm infants exposed to the drug for reasons unrelated to their ductus.

Hoornenborg and colleagues exploited that opportunity in their secondary analysis, asking whether paracetamol given as an analgesic was associated with an increased risk of bronchopulmonary dysplasia in extremely preterm infants. The question matters because acetaminophen is among the most widely administered medications in neonatal intensive care, used for procedural and postoperative pain and increasingly considered for ductal closure. If the drug carried even a modest risk to the developing lung, the population-level consequences could be substantial given how many preterm infants receive it. Sharma and Bhandari frame their commentary around exactly this tension between therapeutic utility and pulmonary safety.

Concern about acetaminophen’s effects on the lung is not merely theoretical. Laboratory studies referenced in the commentary have shown that toxic acetaminophen exposure can induce distal lung endoplasmic reticulum stress, proinflammatory signaling, and emphysematous changes in the adult murine lung, and that the developing murine lung appears susceptible to acetaminophen toxicity in ways independent of the hepatic damage for which the drug is best known. Investigators have also raised the possibility that acetaminophen exposure in early life could have lifelong consequences for respiratory health. On the other side of the ledger, ibuprofen has its own pulmonary profile: animal work has documented vascular and pulmonary effects of ibuprofen on neonatal lung development, and recent studies indicate that inhibition of the mitochondrial integrated stress response can ameliorate ibuprofen-induced endothelial dysfunction in models of neonatal hyperoxia-induced lung injury. Both drug classes, in other words, have biological plausibility for lung effects that clinical trials have so far not translated into clear harm.

Interpreting this literature requires attention to the difficulty of the outcome itself. Bronchopulmonary dysplasia is now understood as a syndrome with multiple pulmonary phenotypes in the preterm infant, and its diagnosis has been refined through evidence-based approaches that grade severity by the level of respiratory support required. Newer tools, including magnetic resonance imaging phenotyping and life-course approaches to lung function monitoring after preterm birth, are reshaping how researchers detect subtle drug effects that survival-based or oxygen-based definitions may miss. The commentary’s authors, who have previously argued that bronchopulmonary dysplasia research must move from the bedside to the bench and back again, emphasize that postnatal inflammation, corticosteroid effects on lung development, and gene-environment interactions all complicate any attempt to isolate the contribution of a single analgesic or anti-inflammatory drug.

Where does this leave clinicians and families? The accumulating trial evidence, from the Gupta ibuprofen trial, the Jensen retrospective comparison, the BeNeDuctus trial, and now the Hoornenborg secondary analysis, points toward a consistent conclusion: neither acetaminophen nor the classical non-steroidal anti-inflammatory drugs, as used in contemporary neonatal practice, has been shown to increase the incidence of bronchopulmonary dysplasia or death in extremely preterm infants. At the same time, Sharma and Bhandari’s commentary underscores that the question of pulmonary safety has not been closed as definitively as the ductus itself. Preclinical signals of lung toxicity, the heterogeneity of bronchopulmonary dysplasia phenotypes, and the possibility of long-term respiratory consequences all argue for continued vigilance. As randomized trials of prophylactic acetaminophen for ductal closure and expectant management strategies continue to mature, the developing lung remains the outcome against which every neonatal drug must ultimately be judged.

Subject of Research: Pulmonary safety of acetaminophen and NSAID treatment for patent ductus arteriosus in preterm infants

Article Title: Does use of acetaminophen and/or NSAIDs increase the risk of developing bronchopulmonary dysplasia?

Article References: Sharma, R., & Bhandari, V. (2026). Does use of acetaminophen and/or NSAIDs increase the risk of developing bronchopulmonary dysplasia?. Pediatric Research. https://doi.org/10.1038/s41390-026-05526-y

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05526-y

Keywords: bronchopulmonary dysplasia, acetaminophen, NSAIDs, patent ductus arteriosus, preterm infants, BeNeDuctus trial, neonatology, ibuprofen, indomethacin, Pediatric Research, lung development, neonatal intensive care

Peptic ulcer bleeding, often abbreviated PUB, is one of the most feared complications in gastroenterology. It occurs when an open sore in the lining of the stomach or the first part of the small intestine erodes into a blood vessel, producing external digestive hemorrhage or a drop in hemoglobin greater than two grams per deciliter. Despite major advances in endoscopic therapy and acid suppression over the past two decades, patients who experience one such bleed remain at elevated risk of another. For those also taking antithrombotic medications—drugs such as antiplatelet agents and anticoagulants that are essential for preventing heart attacks and strokes—the calculus becomes even more delicate, because both the ulcer and the cardiovascular system compete for clinical attention.

The conventional wisdom, embedded in multiple international guidelines, holds that eradicating H. pylori, a spiral-shaped bacterium that colonizes the gastric mucosa and is a principal cause of peptic ulcer disease, is a cornerstone of preventing recurrent bleeding. Yet much of the evidence underpinning that recommendation predates the era of widespread, long-term proton pump inhibitor use, the powerful acid-suppressing drugs that have become near-universal prescriptions after a bleeding event. The Spanish team set out to test whether the bacterium still drives recurrence in a contemporary, real-world population in which acid suppression is the norm rather than the exception.

To answer the question, the investigators conducted a retrospective, multicenter cohort study of consecutive patients who suffered a first episode of peptic ulcer bleeding between 2008 and 2023 in real clinical settings across Spain. To be included, patients required endoscopically confirmed gastric or duodenal ulcers or erosions together with evidence of bleeding. Those with non-peptic causes of upper gastrointestinal hemorrhage, peptic ulcers without bleeding, bleeding from the small bowel or colon, missing clinical data, or death during the index hospitalization were excluded. Follow-up continued until the first recurrence of ulcer bleeding, death, loss to follow-up, or the end of the review period, yielding a mean observation time of 6.4 years with a standard deviation of 4.7 years—a remarkably long window for a study of this kind.

The cohort ultimately comprised 1,675 patients. At discharge after their first bleeding episode, 525 of them, or 31 percent, were prescribed antithrombotic therapy, while 1,021 patients, or 61 percent of the entire cohort, received long-term proton pump inhibitor prescriptions. Notably, among the antithrombotic users themselves, 429 patients, representing 82 percent, were given indefinite PPI therapy, underscoring just how thoroughly acid suppression has penetrated routine care for this group. After the initial bleed and any eradication treatment, 94 patients, or 5.6 percent, remained H. pylori-positive, 936 patients, or 56 percent, tested negative, and 645 patients, or 38 percent, were never tested for the bacterium—a sizable untested fraction that itself reflects themessiness of real-world medicine.

The headline finding for the whole cohort was striking. Overall, 7.2 percent of patients experienced a first recurrence of peptic ulcer bleeding during follow-up. But when the researchers stratified by H. pylori status, recurrence climbed to 22 percent among those who remained positive, fell to 7.7 percent among those who were negative, and dropped to just 4.2 percent among the untested. Using Cox regression analysis adjusted for age, sex, use of non-steroidal anti-inflammatory drugs, and long-term PPI prescription, the team calculated that patients who stayed H. pylori-positive had a 3.7-fold higher risk of recurrence compared with H. pylori-negative patients, with a 95 percent confidence interval of 2.3 to 6.1. When the comparison was restricted to patients who remained positive versus those who had been successfully eradicated, the risk was 4.7 times higher, with a confidence interval of 2.6 to 8.7. In other words, in the general population of bleeders, the bacterium remains a potent and measurable driver of recurrent hemorrhage.

The picture changed dramatically, however, when the researchers turned to the 525 patients on antithrombotic drugs. In this subgroup, the overall incidence of first recurrence was only 5.1 percent. Among H. pylori-positive antithrombotic users, recurrence reached 7.1 percent; among H. pylori-negative users, 8 percent; and among the untested, just 2 percent. Counterintuitively, the positive patients did not fare worse than the negative ones, and after statistical adjustment the team found no significant risk differences across H. pylori status groups. The wide confidence intervals that accompany such subgroup analyses temper any strong claims, but the signal is clear: within this heavily PPI-protected population, H. pylori status no longer predicted who would bleed again.

What might explain this apparent paradox? One plausible mechanism centers on gastric acidity itself. H. pylori promotes ulcer formation and recurrence partly through inflammation and disruption of the mucosal barrier, but acid secretion remains a critical cofactor in the cascade that turns a colonized stomach into a bleeding ulcer. Proton pump inhibitors suppress acid output profoundly and durably, and with 82 percent of antithrombotic users in this cohort taking them indefinitely, the pharmacological floor beneath the mucosa may be high enough that eradicating the bacterium adds little additional protection. In patients without such acid suppression, or in whom PPI therapy is intermittent, the bacterium retains its full pathogenic force—precisely the pattern the whole-cohort analysis revealed. The finding also echoes a broader shift in ulcer epidemiology: as H. pylori prevalence falls and non-steroidal anti-inflammatory drug and antithrombotic use rises, drug-induced mucosal injury has overtaken infection as the dominant cause of bleeding ulcers in many settings.

The authors are careful to frame their work as preliminary, and several limitations deserve attention. The retrospective design means the researchers depended on records and testing practices that varied across centers and years, and the 38 percent of patients never tested for H. pylori introduce the possibility of selection effects—clinicians may have been less likely to test patients they judged to be at low risk. The antithrombotic subgroup, though sizable at 525 patients, yielded relatively few recurrence events, which limits statistical power and widens uncertainty around the null finding. Confounding by indication is also possible, since patients receiving antithrombotics differ systematically from those who do not. The study’s ethics approval came from the ethics committee of Aragón under code EPA22/065, with the informed consent requirement waived owing to the observational design, and the statistical analysis was supported by the Group of Translational Research in Digestive Diseases of the Aragón Health Research Institute, the CIBERehd network, and the FORTALECE program of the Spanish Ministry of Science and Innovation.

Even with those caveats, the implications are hard to ignore. Millions of people worldwide take antithrombotic drugs for cardiovascular protection, and a meaningful share of them carry H. pylori or have uncertain infection status. If prolonged acid suppression largely neutralizes the bacterium’s contribution to recurrent bleeding in these patients, clinicians may be able to prioritize adherence to PPI therapy, careful antithrombotic dosing, and avoidance of non-steroidal anti-inflammatory drugs over exhaustive pursuit of eradication in every case. At the same time, the stark 3.7-fold elevation in recurrence risk among H. pylori-positive patients in the broader cohort is a vivid reminder that eradication remains essential for most survivors of ulcer bleeding. The study does not overturn the eradication paradigm; it carves out a well-defined exception and, in doing so, maps the boundary conditions of one of gastroenterology’s most durable beliefs. Larger prospective studies, ideally with systematic testing of all patients, will be needed to confirm where that boundary truly lies—but for now, the message from Spain is that in the modern, acid-suppressed, real-world clinic, the bacterium’s grip on bleeding risk may be loosening, at least for those whose hearts and vessels demand blood thinners.

Subject of Research: Helicobacter pylori status and recurrence of peptic ulcer bleeding in antithrombotic users

Article Title: No significant association between H. pylori status and peptic ulcer bleeding recurrence among antithrombotic users: a preliminary study in a real-world population with high PPI use

Article References: Martínez-Domínguez, S. J., Ceamanos-Ibarra, E., Gallego-Llera, B., Jiménez-Benedí, M., Bujanda, L., Jardón-Piérola, O., Izaguirre-Arostegi, A., Cuarán, C., Pascual, A., Almenara, L., & Lanas, Á. (2026). No significant association between H. pylori status and peptic ulcer bleeding recurrence among antithrombotic users: a preliminary study in a real-world population with high PPI use. BMC Medicine. https://doi.org/10.1186/s12916-026-05275-z

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05275-z

Keywords: Helicobacter pylori, peptic ulcer bleeding, antithrombotics, proton pump inhibitors, gastrointestinal bleeding, ulcer recurrence, Cox regression, retrospective cohort study, NSAIDs, eradication, BMC Medicine, gastroenterology

The research team, led by investigators at Samsung Medical Center in Seoul, drew on the Korean Nationwide Cancer Public Library Database, a national registry that links cancer diagnoses with prescription records, hospital visits, and death certificates. From this resource they identified 14,736 women newly diagnosed with ovarian or fallopian tube cancer between 2012 and 2019. Because South Korea’s National Health Insurance Service covers virtually the entire population, the database captures an unusually complete picture of real-world medication use, avoiding the recall bias that plagues studies asking patients to remember what they took years earlier.

The investigators classified NSAID exposure in two complementary ways. First, they looked at timing relative to diagnosis: women who filled NSAID prescriptions only within the six months after diagnosis were labeled POST users, while those who used the drugs both before and after diagnosis were labeled PRE and POST users. Second, they measured frequency of use after diagnosis, dividing patients into low users who took NSAIDs less than one day per week, intermediate users taking one to three days per week, and high users taking four or more days per week. This dual classification allowed the team to distinguish whether sustained use around the diagnostic window mattered more than intensity of use afterward.

The biological rationale for the study rests on decades of evidence that inflammation is not merely a symptom of cancer but an active participant in its progression. NSAIDs block cyclooxygenase enzymes, known as COX-1 and COX-2, which convert arachidonic acid into prostaglandins such as prostaglandin E2. In the ovarian tumor microenvironment, prostaglandin E2 has been linked to immune suppression, angiogenesis through vascular endothelial growth factor signaling, and the recruitment of myeloid-derived suppressor cells, all of which can blunt the body’s antitumor defenses and undermine chemotherapy. By dampening these pathways, NSAIDs have shown anticancer effects in other malignancies, including head and neck squamous cell carcinoma, prompting researchers to ask whether the same logic applies to ovarian cancer, a disease notoriously resistant to treatment in its advanced stages.

Over a median follow-up of 2.91 years, 4,108 of the women in the study died, a mortality rate of 27.9 percent. The team used Cox proportional hazards models, the standard statistical framework for survival analysis, adjusting for demographic characteristics, comorbidities measured by the Charlson Comorbidity Index, cancer stage, and treatment-related factors. The results were sobering for those hoping for a simple answer. In the fully adjusted model of the overall cohort, neither the timing of NSAID use nor the frequency of use after diagnosis was significantly associated with all-cause mortality. Women who used NSAIDs both before and after diagnosis had a hazard ratio of 0.94, with a 95 percent confidence interval of 0.88 to 1.01, a range that just crosses the threshold of statistical significance. High-frequency users fared similarly, with a hazard ratio of 0.92 and a confidence interval of 0.82 to 1.04.

But the story changed dramatically when the researchers stratified the cohort by initial treatment sequence, splitting patients into those who received surgery first and those who began with chemotherapy. Among women in the surgery-first group, the associations turned significant. Those who used NSAIDs both before and after diagnosis had a hazard ratio of 0.89, with a confidence interval of 0.82 to 0.97, indicating an eleven percent lower risk of death compared with women who did not. High-frequency users in this subgroup showed an even stronger signal, with a hazard ratio of 0.84 and a confidence interval of 0.73 to 0.98. In the chemotherapy-first subgroup, by contrast, no associations were found at all, regardless of timing or frequency.

Why might surgery-first patients benefit while chemotherapy-first patients show no effect? The authors and observers point to several plausible mechanisms. Surgery itself triggers a profound inflammatory response, releasing cytokines such as tumor necrosis factor-alpha and interleukin-8, and perioperative inflammation is known to suppress tumor-infiltrating lymphocytes, the immune cells that correlate with better outcomes in ovarian cancer. NSAIDs taken around the time of surgery could theoretically blunt this inflammatory surge and preserve antitumor immunity. Patients undergoing chemotherapy first, often those with more advanced or inoperable disease, may represent a biologically different population in which the dominant drivers of mortality are tumor aggressiveness rather than treatment-related inflammation, leaving less room for NSAIDs to matter.

The researchers themselves urge caution, and their language is deliberately restrained. They note that the significant findings in the surgery-first subgroup require cautious interpretation given multiple potential sources of residual confounding. Observational studies of this kind cannot prove causation, and the very fact that NSAID use was associated with benefit in one subgroup but not another raises the possibility of confounding by indication or by underlying health status. Women well enough to undergo primary surgery tend to have earlier-stage disease, better performance status, and different comorbidity profiles than those routed directly to chemotherapy, and even sophisticated statistical adjustment cannot fully erase these differences. Reverse causation is another concern: women with advanced disease may avoid NSAIDs or be prescribed them differently, distorting the apparent relationship between the drugs and survival.

There are also technical limitations inherent to prescription-database research. Over-the-counter NSAID purchases may not be fully captured, meaning some exposure could be misclassified. The study measured all-cause mortality rather than cancer-specific mortality, so deaths from cardiovascular events or other causes dilute any drug-specific signal. The dose and duration of NSAID use were approximated from prescription frequency rather than actual consumption, and the analysis could not distinguish reliably among individual agents, from non-selective NSAIDs such as ibuprofen and naproxen to selective COX-2 inhibitors, each with distinct pharmacology and safety profiles. Supplementary analyses by SEER stage, extent of surgical procedure, and intensive care unit admission were performed to probe the robustness of the findings, but no observational design can eliminate uncertainty entirely.

Still, the scale of the study gives its null and subgroup findings real weight. With nearly fifteen thousand patients drawn from a single-payer national system, this is among the largest investigations of peri-diagnostic NSAID use in ovarian cancer to date, and one of the first in an Asian population, where prior evidence has been sparse. The authors, who declare no competing interests and received no specific funding for the work, emphasize that their results do not support recommending NSAIDs to ovarian cancer patients as a survival intervention. Instead, the surgery-first signal should be viewed as a hypothesis generator, pointing toward randomized or mechanistic studies that could test whether perioperative anti-inflammatory treatment genuinely alters the tumor microenvironment and improves outcomes. Until such evidence arrives, the humble painkillers in nearly every medicine cabinet remain exactly what they have always been for ovarian cancer patients: useful for pain, unproven for survival, and now the subject of a tantalizing question that only further research can answer.

Subject of Research: Peri-diagnostic NSAID use and all-cause mortality in ovarian cancer

Article Title: Peri-diagnostic NSAID use and all-cause mortality in ovarian cancer: nationwide cohort study

Article References: Peri-diagnostic NSAID use and all-cause mortality in ovarian cancer: nationwide cohort study. (n.d.). https://doi.org/10.1186/s13048-026-02278-5

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02278-5

Keywords: ovarian cancer, NSAIDs, all-cause mortality, nationwide cohort, inflammation, COX-2, tumor microenvironment, surgery-first, chemotherapy-first, Korea, survival analysis, epidemiology

The mechanics of a prescribing cascade are deceptively simple, which is precisely what makes them so difficult to catch in busy clinical practice. Consider one of the clearest examples highlighted in the study: non-steroidal anti-inflammatory drugs, or NSAIDs, which are among the most widely used medications for pain relief in older populations. NSAIDs are known to raise blood pressure in many patients. When that rise occurs, it can easily be read as the emergence of hypertension, a genuine and serious condition in its own right, leading to a new prescription for antihypertensive medication. What gets lost in that transaction is the causal thread connecting the two drugs. The patient now takes two medications instead of one, carries the side-effect burden of both, and the underlying trigger, the NSAID itself, remains untouched. The cascade, once established, can continue to grow.

Older adults are especially vulnerable to this pattern for reasons that are both biological and structural. Advanced age typically brings multiple chronic conditions, and multiple conditions mean multiple prescribing physicians, multiple pharmacies and, frequently, a long list of concurrent medications. When a new symptom appears in a patient taking ten or twelve drugs, tracing it back to a specific medication started months earlier is a formidable task for even the most diligent clinician. The symptom is more likely to be attributed to aging, to one of the existing diagnoses, or to a genuinely new disease. Dr. Rochon, who holds the Barry J. Goldlist Chair in Aging and Health at Sinai Health and is a professor of medicine at the University of Toronto, emphasized that these sequences of events are common but often missed in clinical practice. Knowing what medications a patient is taking, when each one was started, and for what indication, she noted, is essential for identifying problematic cascades before they compound.

To move the problem from anecdote to evidence, the research team assembled an interdisciplinary, international group of collaborators and leaders in drug prescribing and geriatric medicine research spanning the United States, Belgium, Italy, Israel and Ireland. The Canadian side of the effort included Sinai Health researchers Drs. Vasily Giannakeas, Nathan Stall and Christina Reppas-Rindlisbacher, along with research staff Wei Wu and Joyce Li. Working with Lavina Matai and Zhiyin Li at ICES, Ontario’s health data institute, the team gained access to population-level prescription data covering the province, an unusually powerful foundation for studying how prescribing patterns unfold across millions of patients over time rather than within the confines of a single clinic or hospital.

The analytical framework rested on work the team had completed previously: with the expertise of twelve international panelists specializing in internal medicine, geriatric medicine and clinical pharmacology, the researchers had compiled a list of sixty-five potentially inappropriate prescribing cascades drawn from the medical literature and expert consensus. Each cascade on that list describes a first drug, a second drug prescribed in response to the first drug’s adverse effect, and a plausible biological mechanism linking the two. The Ontario study then subjected all sixty-five candidates to a rigorous population-level test built on three criteria. First, how common was the initial drug in the population? Second, how often was it actually followed by the second drug in real-world prescribing data? Third, how strong was the observed link between the two prescriptions?

That three-part analysis allowed the researchers to distill the field down to the twenty-four potentially inappropriate prescribing cascades that are both most commonly seen in the Ontario population and most likely to cause harm. The list spans a striking range of everyday therapeutics. Beyond the NSAID-to-blood-pressure-medication pathway, the study points to cascades involving statins, iron supplements and other widely dispensed drugs, illustrating that the risk is not confined to exotic or high-alert medications. It is embedded in the routine, well-intentioned prescribing that happens thousands of times a day across the province. Because the analysis was conducted at the level of an entire population rather than a selected cohort, the findings offer some of the strongest evidence yet that prescribing cascades are a systemic issue rather than a collection of individual clinical errors.

For Dr. Rochon, the findings illuminate a gap that opens quietly, one prescription at a time. Her concern, she explained, is that the conversations between prescribers and patients that would reveal these connections are so often missed, leaving both parties unaware that a sequence of events is unfolding and that the events are connected to one another. Closing that gap, the team argues, requires physicians to treat medication history as a living document that deserves attention at every visit, not merely a static list of current drugs. Clinicians need to ask why each medication was started in the first place, when it was initiated, and whether the newest prescription on the list is genuinely treating a new disease or simply patching over the side effect of an older one. That reflective pause, applied consistently, could interrupt a cascade before a second or third drug is ever added.

The findings carry particular weight for mature women, a population that sits at the center of Dr. Rochon’s research program. Women tend to live with more chronic conditions than men over their lifetimes, are prescribed more drug therapies, and experience more adverse drug events. Each additional medication increases the surface area for harm, and each additional condition complicates the diagnostic picture when a new symptom emerges. A woman managing osteoporosis, arthritis, cardiovascular risk factors and other conditions simultaneously faces a heightened probability that a drug’s side effect will be mistaken for a new diagnosis rather than traced back to its source. The study’s population-level lens makes clear that this is not a marginal concern but a structural feature of how care is delivered to older women, and one that deserves targeted attention in prescribing guidelines and clinical education alike.

The research team’s conclusions point toward concrete, technologically feasible next steps. The first involves automated clinical decision support tools embedded directly in electronic prescribing systems. Such tools could flag a potential prescribing cascade in real time, alerting the prescriber at the exact moment a new prescription is about to be added that the patient is already taking a drug known to produce the symptom now being treated. Delivered at the point of care, this kind of automated awareness could transform prescribing cascades from an invisible population-level phenomenon into a visible, actionable warning. The technology required is not speculative; the underlying data linkages and rule-based logic mirror systems already used to flag drug allergies and dangerous interactions.

The second proposed step is organizational rather than technical: optimizing the role of pharmacists as full members of the care team and integrating them more directly into the prescribing process alongside physicians. Pharmacists possess precisely the expertise needed to spot the signature of a prescribing cascade, a new drug whose start date closely follows an older drug with a known adverse-effect profile, and to initiate a medication review before the cascade deepens. Together, the two strategies address the problem from complementary angles, embedding vigilance in both the software that supports prescribing decisions and the professional relationships that surround them. As populations age and polypharmacy becomes the norm rather than the exception, the Ontario study suggests that the question is no longer whether prescribing cascades cause widespread harm, but how quickly health systems can build the safeguards needed to stop them.

Subject of Research: Potentially inappropriate prescribing cascades in older adults identified through population-level analysis of Ontario prescription data

Article Title: Ontario study identifies potentially harmful drug combinations prescribed to older adults

Article References: Ontario study identifies potentially harmful drug combinations prescribed to older adults. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: prescribing cascades, older adults, polypharmacy, medication safety, geriatric medicine, NSAIDs, blood pressure, statins, clinical decision support, pharmacists, mature women's health, The BMJ